Email this article 
Post a Comment Pharmacoeconomic aspects of glaucoma therapy with prostaglandin analogues in patients with signs of ocular surface disease
- Authors: Rudakova A.V.1
-
Affiliations:
- Saint Petersburg State Chemical Pharmaceutical Academy
- Issue: Vol 8, No 1 (2015)
- Pages: 99-103
- Section: Articles
- URL: https://journals.rcsi.science/ov/article/view/329
- DOI: https://doi.org/10.17816/OV2015199-103
- ID: 329
Cite item
Full Text
Abstract
About the authors
Alla Vsevolodovna Rudakova
Saint Petersburg State Chemical Pharmaceutical AcademyDSci, Prof., Dep. of Management and Economics of Pharmacy
References
- Егоров Е. А., Астахов Ю. С., Еричев В. П., Бойко Э. В., Дога А. В., Рябцева А. А., Сергеев В. П., Ропо А. Оценка эффективности и безопасности глазных капель тафлупрост 0,0015 % без консерванта у пациентов с офтальмогипертензией и открытоугольной глаукомой. Клиническая офтальмология. 2015; 1: 1-6.
- Стандарт первичной медико-санитарной помощи при глаукоме. Утвержден приказом МЗ РФ N1700 н от 29.12.2012. Зарегистрирован в Минюсте России 05.03.2013 N 27485.
- Hommer A., Kimmich F. Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost. Clin. Ophthalmol. 2011; 5: 623-631.
- Janulevičienė I., Derkač I., Grybauskiene L., Paulauskaitė R., Gromnickaite R., Kuzmienė L. Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma. Clin. Ophthalmol. 2012; 6: 103-9.
- Joag M., Thirumurthy V., Jha B., Rathi A., Wadhwani M., Dada T. Comparative evaluation of physical properties of 3 commercially available generic brands of latanoprost with Xalatan. Invest. Ophthalmol. Vis. Sci. 2012; 53: 5096.
- Lu D., Hong L., Xu X., Weber S., Pokabla M., Hein A., Noecker R. Chemical analysis of branded latanoprost 0.005 % compared with commercially available latanoprost formulations. Invest. Ophthalmol. Vis. Sci. 2010; 51: 3162.
- Narayanaswamy A., Neog A., Baskaran M., George R., Lingam V., Desai C., Rajadhyaksha V. A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension. Indian J. Ophthalmol. 2007; 55 (2): 127-31.
- Takada Y., Okada Y., Fujita N., Saika S. A patient with corneal epithelial disorder that developed after administration of a latanoprost generic, but not a brand-name drug, eye drop. Case Rep. Ophthalmol. Med. 2012; 2012: 536746.
- Uusitalo H., Chen E., Pfeiffer N., Brignole-Baudouin F., Kaarniranta K., Leino M., Puska P., Palmgren E., Hamacher T., Hofmann G., Petzold G., Richter U., Riedel T., Winter M., Ropo A. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010; 88: 329-36.
Supplementary files
